Blanket Purchase Agreement 36F79719D0160-36E79719A0027

The provided information describes a Blanket Purchase Agreement (BPA) awarded by the U.S. Department of Veterans Affairs (VA) National Acquisition Center to Catalyst Pharmaceuticals, Inc. The BPA, valued at $5,500,000, is placed against the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and has an ultimate completion date of July 25, 2026. The primary purpose of this BPA is to enable the procurement of the pharmaceutical product Firdapse (amifampridine), an FDA-approved...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian federal agency, to PTC Therapeutics, Inc. as the prime contractor. The BPA, valued at a ceiling of $12,500.00, is for the procurement of EMFLAZA, a medication. The BPA was awarded on March 9, 2024, with a period of performance ending on March 14, 2026. The contract was a single award, with no set-aside used. As a BPA, this contract provides a streamlined mechanism for the agency to order and...

The Blanket Purchase Agreement was awarded as a single award by the Department of Veterans Affairs National Acquisition Center to Aimmune Therapeutics, Inc. The potential value of the BPA is $14 million. The BPA is for the procurement of Palforzia, which is intended to reduce the frequency and severity of allergic reactions to peanuts in patients aged 4 through 17 years. No set-aside was used in the awarding of this BPA. The period of performance for orders placed against the BPA extends through...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian federal agency, to Day One Biopharmaceuticals, Inc. The single-award BPA has a ceiling value of $15,000,000.00 and a period of performance ending on March 7, 2026. The BPA is for the procurement of OJEMDA, though the specific products and services to be delivered are not explicitly stated in the provided information. As a BPA, this contract vehicle allows the agency to place orders for recurring...

The Blanket Purchase Agreement (BPA) is a federal contract indefinite delivery vehicle (IDV) awarded by the National Acquisition Center, a civilian agency within the Department of Veterans Affairs (VA), to Genzyme Corporation, doing business as Sanofi Genzyme. The BPA has a ceiling value of $3,000,000 and a period of performance from June 6, 2024 to June 5, 2026. The purpose of the BPA is to provide the VA with a streamlined contracting method to procure specialty pharmaceutical products,...

This Blanket Purchase Agreement (BPA) was awarded by the Air Force Life Cycle Management Center (AFLCMC) at Wright-Patterson Air Force Base, a defense agency, to Petnet Solutions, Inc., a subsidiary of Siemens Aktiengesellschaft. The BPA has a ceiling value of $623,520 and a period of performance from March 22, 2024 to March 21, 2029. The BPA is for the supply of Amyvid (Florbetapir F-18) Tracer, a radiopharmaceutical product used in positron emission tomography (PET) scans to assist in the...

The Defense Health Agency awarded a blanket purchase agreement to Progenics Pharmaceuticals Inc. to procure PILARIFY (PIFLUFOLASTAT F-18) injection, an imaging agent used in positron emission tomography scans to aid in the detection and localization of prostate cancer. The BPA has a potential value of $250,000 and period of performance through April 2027. Multiple firm fixed price call contracts have been placed against the BPA at various medical treatment facilities for delivery of PILARIFY...

This Blanket Purchase Agreement (BPA) awarded by the National Acquisition Center, a civilian agency of the U.S. federal government, to Genentech USA, Inc. is for the procurement of the pharmaceutical product Evrysdi. Evrysdi is a treatment for spinal muscular atrophy, a rare and severe genetic disease. The single-award BPA has a ceiling value of $1,725,140.20 and a period of performance ending on September 21, 2025. As a prime contractor, Genentech USA, Inc., a foreign-owned, for-profit...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian agency, to Sanofi-Aventis U.S. LLC, a foreign-owned for-profit organization, with no set-aside used. The single-award BPA has a ceiling value of $5,000,000.00 and a period of performance from July 1, 2024, to June 30, 2026. The BPA is for the procurement of TZIELD, a pharmaceutical product. As a BPA, this contract provides a streamlined mechanism for the agency to order and obtain TZIELD from the...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian federal agency, to HRA Pharma America, Inc. as the prime contractor. The BPA has a period of performance from June 10, 2025 to June 9, 2026 and a ceiling value of $1,386,062.00. The BPA is for the procurement of the pharmaceutical products Lysodren and Metopirone. No set-asides were used for this single-award contract. The purpose of this BPA is to establish a contract vehicle through which the...